Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas by Swisher, Elizabeth M et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
Molecular Cancer
Open Access Research
Methylation and protein expression of DNA repair genes: 
association with chemotherapy exposure and survival in sporadic 
ovarian and peritoneal carcinomas
Elizabeth M Swisher*1,2, Rachel M Gonzalez2, Toshiyasu Taniguchi3, 
Rochelle L Garcia4, Tom Walsh2, Barbara A Goff1 and Piri Welcsh2
Address: 1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, 
WA 98195, USA, 2Division of Medical Genetics, Departments of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA, 
3Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA and 
4Department of Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA
Email: Elizabeth M Swisher* - swishere@u.washington.edu; Rachel M Gonzalez - rmgher@myuw.net; Toshiyasu Taniguchi - ttaniguc@fhcrc.org; 
Rochelle L Garcia - rochelle@u.washington.edu; Tom Walsh - twalsh@u.washington.edu; Barbara A Goff - bgoff@u.washington.edu; 
Piri Welcsh - piri@u.washington.edu
* Corresponding author    
Abstract
Background: DNA repair genes critically regulate the cellular response to chemotherapy and epigenetic
regulation of these genes may be influenced by chemotherapy exposure. Restoration of BRCA1 and
BRCA2 mediates resistance to platinum chemotherapy in recurrent BRCA1 and BRCA2 mutated
hereditary ovarian carcinomas. We evaluated BRCA1, BRCA2, and MLH1 protein expression in 115
sporadic primary ovarian carcinomas, of which 31 had paired recurrent neoplasms collected after
chemotherapy. Additionally, we assessed whether promoter methylation of BRCA1, MLH1 or FANCF
influenced response to chemotherapy or explained alterations in protein expression after chemotherapy
exposure.
Results: Of 115 primary sporadic ovarian carcinomas, 39 (34%) had low BRCA1 protein and 49 (42%)
had low BRCA2 expression. BRCA1 and BRCA2 protein expression were highly concordant (p < 0.0001).
MLH1 protein loss occurred in 28/115 (24%) primary neoplasms. BRCA1 protein loss in primary
neoplasms was associated with better survival (p = 0.02 Log Rank test) and remained significant after
accounting for either stage or age in a multivariate model (p = 0.04, Cox proportional hazards). In paired
specimens, BRCA1 protein expression increased in 13/21 (62%) and BRCA2 protein expression increased
in 15/21 (71%) of recurrent carcinomas with low or intermediate protein in the paired primary. In contrast
MLH1 expression was rarely decreased in recurrent carcinomas (1/33, 3%). Similar frequencies of MLH1,
BRCA1, and FANCF promoter methylation occurred in primary carcinomas without previous
chemotherapy, after neoadjuvant chemotherapy, or in recurrent neoplasms.
Conclusion: Low BRCA1 expression in primary sporadic ovarian carcinoma is associated with prolonged
survival. Recurrent ovarian carcinomas commonly have increased BRCA1 and/or BRCA2 protein
expression post chemotherapy exposure which could mediate resistance to platinum based therapies.
However, alterations in expression of these proteins after chemotherapy are not commonly mediated by
promoter methylation, and other regulatory mechanisms are likely to contribute to these alterations.
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Background
Ovarian carcinoma is the most deadly gynecological
malignancy and is the fifth leading cause of carcinoma
death in American women. Ovarian carcinomas are usu-
ally responsive to initial platinum based chemotherapy
regimens. However, even after a complete clinical
response, most ovarian carcinomas do recur, with resist-
ance to platinum therapy developing after one or more
chemotherapy courses. Acquired chemotherapy resistance
is one of the greatest clinical challenges in the treatment
of women with ovarian carcinoma.
Germline mutations in the BRCA1 and BRCA2 genes con-
fer inherited susceptibility to ovarian and breast carcino-
mas. Breast and ovarian carcinomas in BRCA1 or BRCA2
mutation carriers usually have somatic deletions of the
wildtype allele, rendering the neoplasm BRCA1 or BRCA2
deficient. BRCA2 is identical to the Fanconi anemia (FA)
gene FANCD1[1]. BRCA1, BRCA2, other FA genes, and a
larger number of protein partners (including the DNA
mismatch repair protein MLH1) are part of a complex
DNA damage response network (reviewed in[2]). In vitro
studies indicate that BRCA1 and BRCA2 loss increases
sensitivity to agents that cause double strand DNA breaks
and/or interstrand DNA cross-links including platinum
agents [3-5]. Conversely, loss of BRCA1 or BRCA2 may
increase resistance to microtubule interfering agents such
as taxanes and vincristine [6,7]. Most studies report
improved survival in women with ovarian carcinomas
associated with BRCA1 and BRCA2 mutations compared
to women with sporadic ovarian carcinoma, consistent
with increased sensitivity to platinum-based chemother-
apy [8-10]. We and others have recently shown that carci-
nomas from patients with inherited frameshift mutations
in BRCA1 or BRCA2 exposed to chemotherapy can
acquire secondary mutations that restore the reading
frame of BRCA1 or BRCA2, resulting in platinum resist-
ance [11-13]. Thus, restoration of expression of proteins
in the FA-BRCA DNA damage response pathway may
increase resistance to platinum and potentially other
agents that induce DNA damage.
While germline mutations in BRCA1 and BRCA2 predis-
pose to hereditary ovarian carcinoma, somatic mutations
in these genes are rare in sporadic ovarian carcinomas [14-
17]. However, epigenetic alterations in these and other
DNA repair genes may play important roles in sporadic
ovarian and breast carcinomas and could contribute to
responsiveness to chemotherapy. Promoter methylation
leads to decreased expression of BRCA1, MLH1, and
FANCF protein in a subset of ovarian carcinomas [18-23].
BRCA1 promoter methylation occurs in 5–20% of spo-
radic ovarian carcinomas[20,22,24,25], while BRCA2
methylation is rare[26,27]. FANCF is a key regulator of the
FA-BRCA pathway[23]. Epigenetic regulation of gene tran-
scription through promoter methylation or histone
acetylation could be a modifiable mechanism of sensitiv-
ity or resistance to chemotherapy. Indeed, in vitro data
indicate that epigenetic alterations in MLH1 and FANCF
modulate response to platinum agents in cell lines
[23,28]. While loss of BRCA1, BRCA2, or FANCF confers
sensitivity to platinum, loss of MLH1 confers resistance to
platinum agents [28]. The importance of these mecha-
nisms in in vivo chemoresistance in ovarian carcinomas
has not been defined.
We undertook this study to determine if protein expres-
sion and/or promoter methylation of BRCA1, MLH1,
BRCA2 and FANCF predicted overall survival in primary
sporadic ovarian carcinomas and whether promoter
methylation or protein expression were altered by expo-
sure to chemotherapy in recurrent carcinomas. We also
wanted to determine the relationship of alterations of
proteins in the FA-BRCA pathway with alterations in p53,
another key sensor of DNA damage.
Results
BRCA1, MLH1 and BRCA2 protein expression in primary 
ovarian carcinomas
Protein expression for BRCA1, MLH1 and BRCA2 was
assessed with immunohistochemistry in 115 sporadic pri-
mary invasive neoplasms. In 31 cases, we had paired
recurrent or persistent neoplasm tissue available after
chemotherapy which allowed for comparison of protein
expression with the matched primary. Eight primary inva-
sive carcinomas were classified as peritoneal in origin and
the remainder ovarian in origin (Table 1). Clinical and
pathological characteristics and relationship to BRCA1
protein expression are summarized in Table 1. Peritoneal
carcinomas were less likely to have low BRCA1 protein
than ovarian carcinomas (p = 0.049, Fishers Exact, two-
tailed). There was no association between BRCA1 protein
expression and grade, histology, or adequacy of surgical
cytoreduction. Stage I carcinomas were more likely to
have normal BRCA1 protein expression compared to stage
II-IV carcinomas (p = 0.03, Fisher exact, two-tailed). As
expected both stage I and II carcinomas were also more
likely to have non serous and undifferentiated histologies
(8/11, 73% for stage I and 3/4 for stage II, p < 0.0001 com-
pared to stage III and IV, Fishers Exact, two-tailed). Stage I
histologies included two serous, one undifferentiated car-
cinoma, one small cell, two mucinous, five endometrioid,
while stage II included 3 endometrioid and one serous.
However, normal BRCA1 protein expression was associ-
ated with Stage I disease and not histology. Both serous
stage I carcinomas had normal BRCA1 protein expression
and 2/3 of endometrioid stage II carcinomas had low
BRCA1 protein expression.
BRCA1, BRCA2, and MLH1 protein expression is summa-
rized in Table 2 and representative staining is shown in
Figure 1. BRCA1 and BRCA2 protein levels were signifi-Molecular Cancer 2009, 8:48 http://www.molecular-cancer.com/content/8/1/48
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cantly and positively correlated (p < 0.0001, two-tailed).
BRCA1 and BRCA2 protein expression were not related to
MLH1 protein expression.
BRCA1, MLH1 and BRCA2 protein expression in paired 
primary and recurrent ovarian carcinomas
MLH1, BRCA1, and BRCA2 protein expression was also
assessed in 31 matched primary and recurrent ovarian car-
cinomas from the same patient to determine if chemo-
therapy influenced MLH1, BRCA1, or BRCA2 protein
levels. In 7 cases a second recurrence was available for
expression analyses. For second recurrences, data was tab-
ulated as if for a separate case when compared to the pri-
mary. Recurrent neoplasms were obtained at varying time
intervals from last chemotherapy. We separated matched
pairs into two groups depending on the interval since last
chemotherapy exposure (≤ six months or >six months).
Complete data for protein and methylation analyses for
each case is presented in Table S1; Additional file 1.
Changes in protein expression in paired neoplasms are
shown schematically in Figure 2 and representative stain-
ing in Figure 3.
Increased BRCA1 or BRCA2 protein would be expected to
increase resistance to platinum therapy. In contrast,
decreased MLH1 protein should be associated with plati-
num resistance. In the paired sets most primary neo-
plasms (26/31, 84%) had normal MLH1 protein. Of the
33 recurrences occurring in the 26 cases with normal
MLH1 protein in the primary, only one had loss of MLH1
Table 1: Clinicopathological characteristics of the sporadic neoplasms studied and BRCA1 protein expression.
BRCA1 Protein Expression
All Cases Low Intermediate Normal p value
Primary site
Ovarian 107 (93%) 39 27 41 p = 0.05
Peritoneal 8 (7%) 0 3 5
Grade
Grade 1 6 (5%) 3 2 1
Grade 2 16 (16%) 5 3 8 NS
Grade 3 93 (79%) 31 25 37
Histology
Serous 81 (70%) 28 24 29 NS
Endometrioid 11 (10%) 4 2 5
Carcinoma NOS 12 (10%) 3 3 6
MMMT 4 (3%) 1 1 2
Clear Cell 1 (1%) 0 0 1
Mucinous 3(3%) 1 0 2
Other* 3 (3%) 2 0 1
Stage
I 11 (10%) 2 1 8 p = 0.03
II 4 (3%) 3 0 1
III 83 (72%) 28 26 29
IV 17 (15%) 6 3 8
Cytoreduction
Optimal (< 1 cm) 73 24 18 31 NS
Suboptimal 36 14 9 13
Not Available 6 1 3 2
Total 116 39 (36%) 30 (26%) 46 (38%)
* Other histologies included one small cell, one transitional cell carcinoma and one carcinoma with focal giant cells.
Table 2: Protein expression in primary sporadic ovarian and 
peritoneal carcinomas before chemotherapy exposure.
Protein Expression
Low
(≤10%)
Intermediate
(10–30%)
Normal
(>30%)
Total
BRCA1 expression 39 (34%) 30 (26%) 46 (40%) 115
BRCA2 expression 49 (42%) 28 (24%) 38 (33%) 115
MLH1 Expression* 28 (24%) 87 (76%)* 115
MLH1 expression was scored in two categories: ≤10% positive cells = 
Low, >10% positivity = Normal.Molecular Cancer 2009, 8:48 http://www.molecular-cancer.com/content/8/1/48
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protein (3.0%, Figures 2 and 3, and Table S1 in Additional
file 1). Neither the primary nor recurrent neoplasm in this
pair had MLH1 promoter methylation.
In contrast to MLH1, BRCA1 and BRCA2 expression dem-
onstrated greater variability between paired primary and
recurrent neoplasms (Figure 2, Table S1;Additional file 1).
In 16 carcinomas recurring after 13 primaries with normal
BRCA1 expression, 13(81%) maintained similar protein
expression and three (19%) demonstrated decreased
BRCA1 expression in the recurrence. In 13 recurrences
that followed 11 paired primaries with intermediate
BRCA1 expression, four had reduced, seven had increased
and two had similar BRCA1 expression in the paired
recurrence. In eight recurrences that followed six primary
carcinomas with low BRCA1 expression, 2 had similar
and six (75%) had increased BRCA1 expression in the
recurrence. Overall 13 of 21 (62%) neoplastic pairs with
low or intermediate BRCA1 protein expression in the pri-
mary had increased BRCA1 protein in the recurrence. In
contrast, only eight of 33 (24%) neoplasms with normal
or intermediate BRCA1 expression showed reduced
BRCA1 expression in the recurrence (p = 0.01). Therefore,
increases in BRCA1 expression were more common than
decreases in BRCA1 expression following chemotherapy.
BRCA2 protein expression also frequently varied between
paired primary and recurrent neoplasms (Figures 2 and 3,
Additional file 1). Among primary neoplasms with low or
intermediate BRCA2 expression, the paired post-chemo-
therapy specimen had increased BRCA2 expression in 15/
21 cases (71%). In contrast to the observation for BRCA1
protein expression, primary neoplasms with normal or
intermediate BRCA2 expression were equally likely to
have decreased BRCA2 expression (14/23, 61%).
Excluding those cases with normal BRCA1 and BRCA2
protein expression in the primary, 20 (80%) recurrent car-
cinomas had increases in either BRCA1 or BRCA2 protein
while five (20%) did not have an increase in expression of
either protein. Likelihood of a complete response to sub-
sequent chemotherapy was not related to whether
increased BRCA1 or BRCA2 protein was identified in the
paired recurrence, but wide heterogeneity in treatment
precludes assessment of response to specific agents.
BRCA1, MLH1, and FANCF promoter methylation in 
primary and recurrent ovarian carcinomas
Methylation was assessed for MLH1, BRCA1 and FANCF
in 104 primary and 36 recurrent sporadic carcinomas. Of
the primary carcinomas tested for methylation, 11 were
obtained after neoadjuvant chemotherapy and 93 were
chemotherapy-naive. Results of methylation analysis for
BRCA1, FANCF and MLH1 are summarized in Table 3. In
no cases were neoplasms methylated at more than one of
these genes. Methylation did not vary between primary
cases exposed to neoadjuvant chemotherapy or in primary
vs. recurrent cases for any gene (Table 3). Ten of the pri-
mary and recurrent neoplasms were matched specimens
from the same patient collected at two different time
points (Table S1; Additional file 1). All ten cases showed
concordant methylation between primary and recurrence,
and none were methylated at any of the three genes.
Reduction of BRCA1 protein was significantly associated
with BRCA1 methylation (p = 0.02). However, BRCA1
methylation only accounted for 7/52 (13.5%) of those
sporadic carcinomas with low or intermediate BRCA1
expression.
All cases with MLH1 methylation demonstrated microsat-
ellite instability at BAT26 (data not shown). MLH1 meth-
ylation was associated with loss of protein (p = 0.03), but
one methylated case did have apparently normal MLH1
protein expression. MLH1 methylation was more com-
mon in endometrioid ovarian carcinomas compared to all
other histologies (3/14, 21% versus 1/116, 1%, p =
Representative protein expression of BRCA1, BRCA2 and  MLH1 in sporadic ovarian carcinomas Figure 1
Representative protein expression of BRCA1, 
BRCA2 and MLH1 in sporadic ovarian carcinomas. 
Protein expression is represented by brown stain. Black bars 
in the lower left corners represent 10 microns. A. BRCA1 
protein in a neoplasm with low expression. B. BRCA1 pro-
tein in a neoplasm with normal expression. C. BRCA2 pro-
tein in a neoplasm with low expression. D. BRCA2 protein in 
a neoplasm with normal expression. E. MLH1 protein in a 
neoplasm with low expression. F. MLH1 protein in a neo-
plasm with normal expression.Molecular Cancer 2009, 8:48 http://www.molecular-cancer.com/content/8/1/48
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Schematic of BRCA1, BRCA2, and MLH1 protein expression in paired primary and recurrent neoplasms Figure 2
Schematic of BRCA1, BRCA2, and MLH1 protein expression in paired primary and recurrent neoplasms. Each 
neoplasm is represented by a single horizontal line. A. BRCA1 protein expression in 24 primary and paired recurrent neo-
plasms obtained ≤ 6 months since last chemotherapy, 8 with second recurrences. B. BRCA1 expression in 7 primary and 
paired recurrent neoplasms in which the recurrence was obtained more than 6 months since last chemotherapy. C. BRCA2 
protein expression in 24 primary and paired recurrent neoplasms obtained ≤ 6 months since last chemotherapy. D. BRCA2 
expression in 7 primary and paired recurrent neoplasm obtained more than 6 months since last chemotherapy. E. MLH1 pro-
tein expression in 24 primary and paired recurrent neoplasms obtained ≤ 6 months since last chemotherapy. F. MLH1 expres-
sion in 7 primary and paired recurrent neoplasm obtained more than 6 months since last chemotherapy.Molecular Cancer 2009, 8:48 http://www.molecular-cancer.com/content/8/1/48
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0.003). FANCF and BRCA1 methylation were not associ-
ated with histology.
Relationship of p53 mutations to protein expression and 
methylation of DNA repair genes
p53 mutations were assessed by DNA sequencing in all
cases tested for methylation and neither BRCA1, MLH1,
nor FANCF methylation were associated with p53 muta-
tion status. p53 mutations were more common in spo-
radic ovarian carcinomas with loss or reduction of BRCA1
expression (Table 4, p = 0.01 Fishers Exact). The majority
of p53 mutations were missense mutations occurring in
the DNA binding domain (exons 5–8). Null mutations
including frameshift, splice site, and nonsense mutations
accounted for 9/33 (27%) of p53 mutations.
Overall survival and protein expression or promoter 
methylation
Individual factors influencing survival in this cohort in
univariate analyses were stage (p = 0.01), age (p = 0.03)
and optimal cytoreduction to a maximum neoplastic
diameter less than 1 cm (p < 0.0001) and low BRCA1
expression (p = 0.02). Low BRCA1 expression in the pri-
mary carcinoma was associated with longer survival com-
pared to intermediate or normal BRCA1 expression
(median survival 62 months vs. 45 months, p = 0.02
LogRank Test, Hazard Ratio 0.59, 95% confidence interval
0.37–0.93, Figure 4). Low BRCA1 expression remained
significantly associated with improved survival in a Cox
multi regression model with the covariates age (p = 0.04)
or stage (p = 0.04) but was no longer significant when
using the co-variate optimal cytoreduction (p = 0.10).
Individual factors not related to survival included grade,
MLH1 or BRCA2 protein expression, methylation of
BRCA1, MLH1 or FANCF genes, or p53 mutation.
Response to chemotherapy
The likelihood of a complete response to initial chemo-
therapy was not related to BRCA1 protein levels. Likewise,
there was no significant difference in the complete
response rate for cases with BRCA1 methylation, MLH1
methylation, or for cases with either BRCA1 or FANCF
methylation.
Discussion
BRCA1 protein loss is common in sporadic epithelial
ovarian and peritoneal carcinomas. Low BRCA1 protein
expression was associated with a significantly improved
overall survival. Our data suggest that somatic loss of
BRCA1 favourably influences survival similar to the
BRCA1, BRCA2, and MLH1 protein expression in paired pri- mary and recurrent neoplasms Figure 3
BRCA1, BRCA2, and MLH1 protein expression in 
paired primary and recurrent neoplasms. Protein 
expression is represented by brown stain. Black bars in the 
lower left corners are equal to 10 microns. A. BRCA1 
expression is low in the primary neoplasm. B. BRCA1 
expression is increased in the paired recurrent neoplasm. C. 
BRCA2 protein expression is low in a different primary neo-
plasm. D. BRCA2 expression is increased in the paired recur-
rent neoplasm. E. MLH1 protein is normal in a different 
primary neoplasm. F. In the paired recurrent neoplasm, 
MLH1 protein expression is reduced.
Table 3: Methylation of DNA repair genes in primary and recurrent ovarian or peritoneal carcinomas.
PROPORTION METHYLATED
BRCA1 MLH1 FANCF
Primary, no chemotherapy 6/91 (6.6%) 3/93 (3.2%) 3/93 (3.2%)
Primary, post neoadjuvant chemo 2/11 (18%) 1/11 (9.1%) 0/10
Recurrent* 2/31 (6.5%) 0/30 0/31 (0%)
Total (2.2%) 10/133 (7.5%) 4/134 (3.0%) 3/134
* Ten recurrent carcinomas were paired specimens for which we also evaluated the primary neoplasm. None of these 10 paired cases were 
methylated at any of the three genes in either the primary or recurrent case. One of these 10 pairs did show loss of MLH1 protein in the recurrent 
neoplasm, but was not methylated.Molecular Cancer 2009, 8:48 http://www.molecular-cancer.com/content/8/1/48
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improved survival in ovarian carcinomas associated with
inherited BRCA1 mutations. Two previous studies have
examined the relationship between BRCA1 protein
expression and prognosis in ovarian carcinomas. Thrall
and colleagues evaluated a large number of sporadic
advanced stage carcinomas and found that BRCA1 loss
was strongly protective for overall survival [29]. In
another study of un-selected ovarian carcinoma, Wang
and colleagues failed to find an association between
BRCA1 protein and prognosis [30]. However, that series
evaluated a large number of endometrioid, clear cell,
grade 1 and stage I cases, with few high-grade, advanced
stage, serous carcinomas, distinctly different from the
neoplasms in our study. Indeed, among the 29 stage III
and IV cases in Wang's study, there was a trend toward a
survival advantage with loss of BRCA1 protein [30]. Our
data combined with these two previous studies confirm
an improved prognosis for women with advanced ovarian
carcinomas with low BRCA1 protein expression.
To our knowledge, this is the first study of BRCA2 protein
expression in human ovarian carcinomas. Unlike BRCA1,
BRCA2 protein expression was not associated with overall
survival. Our data demonstrate that BRCA1 and BRCA2
protein expression are highly concordant in ovarian carci-
nomas. In both mouse and human, BRCA1 and BRCA2
have nearly identical patterns of message and protein
expression in embryonic development, breast morpho-
genesis, and in many adult tissues, suggesting that the two
genes share regulatory networks [31-34]. Similarly, in
breast and ovarian carcinoma cell lines, BRCA1 and
BRCA2 mRNA are concordantly induced by adriamycin,
ionizing radiation, and estrogen [35-37]. Our data suggest
that ovarian carcinomas maintain the coordinate regula-
tion of BRCA1 and BRCA2 seen in normal tissues.
We hypothesized that BRCA1 and BRCA2 protein levels
would increase after exposure to chemotherapy, thereby
mediating increasing platinum resistance during the dis-
ease course. Since recurrent ovarian carcinomas are not
routinely subjected to biopsy, our cases represent a wide
variety of disease time points depending on the clinical
indication for biopsy or surgery in a given patient. Conse-
quently, our patients received varied amounts and types
of chemotherapy before and after biopsies. An increase in
BRCA1 or BRCA2 protein occurred in the majority of
recurrent neoplasms that had low or intermediate protein
in the paired primary. Increases in BRCA1 protein were
significantly more likely than reduction of protein in
paired post chemotherapy neoplasms, suggesting a selec-
tion for increased BRCA1 expression. In contrast, BRCA2
protein both increased and decreased frequently post
chemotherapy. An increasing tendency toward platinum
resistance during the typical ovarian carcinoma disease
course is a well recognized clinical challenge. Increased
BRCA1 and BRCA2 expression could mediate that resist-
ance. However, given the treatment heterogeneity of our
cases, we cannot directly relate the alterations in BRCA1 or
BRCA2 expression with specific treatment responses.
Our data are consistent with previous reports that BRCA1
promoter methylation occurs in 5–20% of sporadic ovar-
ian carcinomas [20-22,24,25]. Interestingly, we found
Table 4: p53 mutations and BRCA1 protein level in primary sporadic ovarian carcinomas
P53 Mutations
BRCA1 protein Expression Total Tested Missense
N (%)
Null
N (%)
Total P53 mutations
Low 28 10 (36%) 5 (18%) 15 (54%)
Intermediate 18 8 (44%) 2 (11%) 10 (56%)
Normal 33 6(18%) 2 (6%) 8 (24%)*
Total 79 24 (30%) 9 (11%) 33 (42%)
*p = 0.01 for difference in p53 mutation frequency for cases with normal versus reduction or loss of BRCA1 protein.
Overall survival in relation to BRCA1 expression in primary  sporadic ovarian carcinomas Figure 4
Overall survival in relation to BRCA1 expression in 
primary sporadic ovarian carcinomas. Overall survival 
was significantly improved in primary ovarian carcinomas (p 
= 0.02, LogRank test) with low BRCA1 protein expression 
(median survival 62 months) compared to carcinomas with 
intermediate or normal BRCA1 expresssion (median survival 
45 months).Molecular Cancer 2009, 8:48 http://www.molecular-cancer.com/content/8/1/48
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that promoter methylation only occurs in 15% of those
sporadic ovarian carcinomas with low or intermediate
BRCA1 expression. Thus, other regulators of BRCA1
expression may be more important than promoter meth-
ylation in ovarian carcinomas for both primary and recur-
rent neoplasms. We found no association between BRCA1
methylation and survival in sporadic ovarian carcinomas,
in contrast to a recent small study that demonstrated a sur-
vival disadvantage for patients whose neoplasms were
methylated at BRCA1 [38]. Our data suggest that BRCA1
protein expression is a better predictor of survival than
BRCA1 promoter methylation, not surprising given the
relatively small number of cases with BRCA1 methylation.
Low BRCA1 protein expression was associated with an
increased likelihood of p53 mutation, low BRCA2 protein
expression, and improved survival. Only one previous
study of which we are aware has examined the association
of somatic BRCA1 alterations and p53 status. In that
study, BRCA1 methylation did not correlate with immu-
nohistochemically detected p53 protein expression [22].
However, p53 immunohistochemistry correlates imper-
fectly with the presence of a somatic mutation, and
BRCA1 methylation accounts for only a small fraction of
BRCA1 protein loss, so our studies are not equivalent. The
majority of breast, ovarian, and peritoneal carcinomas
associated with germline mutations in BRCA1 and BRCA2
have p53 mutations, at rates higher than found in their
sporadic counterparts [39-42]. Thus, many sporadic ovar-
ian carcinomas have reduction of BRCA1 protein, muta-
tions in p53, and better overall survival, mimicking the
phenotype of hereditary BRCA1-associated ovarian carci-
noma.
MLH1 is a DNA mismatch repair gene required for sensi-
tivity to platinum compounds. MHL1 is commonly meth-
ylated in colorectal and endometrial carcinomas and less
commonly in ovarian carcinomas [19,24]. MLH1 methyl-
ation mediates platinum resistance in the ovarian carci-
noma cell line A2780 [18]. We postulated that
chemotherapy exposure could select for neoplastic cells
with MLH1 methylation. Indeed, cell-free methylated
MLH1 DNA is increased in the plasma of women with
ovarian carcinoma at the time of clinical relapse [43].
Increased methylation of MLH1 in recurrent ovarian car-
cinoma has been proposed as a rationale for clinical trials
of demethylating agents alone or in combination with
chemotherapy. We found no association between MLH1
protein and overall survival or response to chemotherapy,
and we rarely observed (3.8%) loss of MLH1 protein in
paired neoplasms following chemotherapy exposure. Our
data contrast with those of two groups who both reported
a significant decrease in MLH1 protein expression in
paired ovarian carcinomas following platinum chemo-
therapy [44,45]. But surprisingly, Fink and colleagues
found that MLH1 protein expression correlated inversely
with treatment response, opposite to the expected associ-
ation [44]. We used a traditional cut-off to define MLH1
protein deficiency at 10% of cells while the other two
studies used a continuous scoring system. However, even
when we re-evaluated our data with a continuous scoring
system, we still found that significant decrease in MLH1
protein expression was rare (data not shown). The dis-
crepancies between these studies and ours may stem from
the clinical heterogeneity of cases for which paired pri-
mary and recurrent ovarian carcinomas are available.
Finally, we did not find MLH1 promoter methylation
more frequently in either recurrent neoplasms or in pri-
mary neoplasms exposed to neoadjuvant chemotherapy,
nor was MLH1 methylation identified in the neoplastic
pair with reduced MLH1 expression in the recurrence.
Consequently, our data do not support a major role for in
vivo epigenetic alteration of MLH1 expression in the devel-
opment of clinical platinum resistance in sporadic ovar-
ian carcinomas.
FANCF may also mediate platinum sensitivity. FANCF
promoter methylation confers cisplatin sensitivity to cell
lines and was hypothesized to be a mediator of in vivo
platinum sensitivity[23]. In order to mediate resistance, a
neoplasm should be initially methylated and then lose
methylation in recurrent disease. However, our findings
indicate that FANCF methylation occurs rarely in primary
ovarian carcinomas (<5% of cases), and is therefore not
likely to be a major clinical mediator of platinum sensitiv-
ity.
Conclusion
Low BRCA1 protein expression in sporadic ovarian carci-
nomas is associated with a favourable survival and an
increased rate of p53 mutations. BRCA1 and BRCA2 pro-
teins are concordantly expressed in sporadic ovarian and
peritoneal carcinomas. Increases in BRCA1 and BRCA2
protein expression are common in recurrent sporadic
ovarian carcinomas, but the mechanism(s) responsible
for these expression differences are unknown. Alteration
in methylation of the promoters of BRCA1, MLH1, and
FANCF do not seem to commonly mediate clinical chem-
oresistance in women with ovarian carcinomas.
Methods
Specimens
Patients consented to have tissue collected and to provide
blood samples using protocols approved by the Human
Subjects Division of the University of Washington Institu-
tional Review Board. Paraffin blocks were obtained from
pathology archives. Tissues were obtained at the time of
surgery and snap frozen in liquid nitrogen. Tissue sections
were stained with hematoxylin and eosin and reviewed
for neoplastic cell percentage prior to DNA extraction.
DNA was extracted using the Stratagene® kit according to
the manufacturer's instructions. Normal DNA wasMolecular Cancer 2009, 8:48 http://www.molecular-cancer.com/content/8/1/48
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extracted from peripheral white blood cells or from nor-
mal tissue after histological review excluded contamina-
tion with neoplasm. Family history was considered strong
if the patient had a known BRCA1 or BRCA2 mutation,
personal history of breast carcinoma, any relative with
ovarian carcinoma, a first degree relative with premeno-
pausal breast carcinoma, or two relatives of any degree
with breast carcinoma at any age. Cases without strong
family histories were considered sporadic, while those
with suggestive family histories were considered familial
and excluded.
Immunohistochemical staining for MLH1, BRCA1 and 
BRCA2
BRCA1 protein was detected in formalin fixed paraffin
sections using the mouse monoclonal antibody MS110
(previously called Ab-1, Oncogene Research Products) as
previously described [46]. The MS110 antibody recog-
nizes an amino terminal epitope in BRCA1 (amino acid
residues 89–222). BRCA2 was detected using the H-300
rabbit polyclonal antibody (Santa Cruz Biotech) that rec-
ognizes amino acid residues 2520–2819 of human
BRCA2. MLH1 was detected using the mouse monoclonal
antibody G168-728 (BD Pharmingen). Briefly, paraffin
sections were deparaffinized, re-hydrated, and treated
with steam heat for 20 minutes using antigen target
retrieval solution (DAKO). Endogenous peroxidase activ-
ity was quenched by treatment with 3% H2O2 for 5 min-
utes. Sections were washed with PBS and non-specific
binding was blocked by treatment for three hours in 2%
bovine serum albumin in PBS. Primary antibody was
diluted in PBS (MS110 at 1:250 dilution, H-300 at 1:100
dilution, and G168-728 at 1:80) and applied to sections
for 14–16 hours at 4° (MS110 and H-300) or 40 minutes
at room temperature (G168-728). Secondary antibody
and streptavidin biotin-peroxidase were from Universal
Large Volume LSAB+, Peroxidase kit (DAKO) and were
each applied for 30 minutes at room temperature. DAB
(3,3'diaminobenzidine)-nickel or DAB chromagen
(DAKO) was used to visualize antibody complexes. Sec-
tions were counterstained with methyl green or hematox-
ylin. Staining of inflammatory cells served as a positive
internal control for all antibodies.
In order to demonstrate the specificity of the BRCA2 H-
300 antibody we tested our protocol on a primary tumor
with a BRCA2 mutation that results in protein truncation
prior to the epitope recognized by H-300. This carcinoma
has no detectable wildtype sequence. We also evaluated
BRCA2 on its paired recurrence with a known genetic
reversion and presumed normal expression of
BRCA2[12]. Protein expression was absent in the primary
carcinoma and strongly present in all recurrent neoplastic
nuclei consistent with the DNA sequence information
(data not shown).
Controversy exists regarding the meaning and specificity
of cytoplasmic staining for BRCA1 and BRCA2. Proteins
encoded by aberrantly spliced isoforms have been shown
to localize to the cytoplasm for both BRCA1 and BRCA2
[47-49]. The MS110 antibody has better specificity than
other anti-BRCA1 antibodies and has an almost exclu-
sively nuclear staining pattern[46]. We observed exclu-
sively nuclear BRCA1 protein staining in both normal and
neoplastic tissues. We observed both nuclear and cyto-
plasmic BRCA2 staining in neoplastic cells, but scored
only nuclear staining as likely to be relevant to intact DNA
repair. BRCA1 and BRCA2 protein was scored as previ-
ously described: "low" if fewer than 10% of neoplastic
cells had nuclear staining and "intermediate" if 10% to
30% of neoplastic cells had nuclear staining and normal
if greater than 30% of neoplastic cells had nuclear staining
[46]. MLH1 protein expression was scored as loss (<10%
of cells positive) or normal (>10% of cells positive) as is
done routinely for clinical purposes. MLH1 staining was
exclusively nuclear. For the purpose of comparing protein
expression in paired primary and recurrent neoplasms,
the second recurrence in those seven cases with more than
one recurrence was compared with the primary neo-
plasms and counted as a separate case.
Methylation specific PCR
Carcinomas were evaluated for BRCA1, MLH1 and FANCF
promoter methylation as previously described [21,23,50].
All methylation specific PCR assays included a positive
control (in vitro methylated DNA, Invitrogen) and a neg-
ative (water) control. Positive assays were repeated at least
once. Sodium bisulfite treated DNA was amplified with
primers specific for either methylated or unmethylated
treated substrate. PCR products were electrophoresed on
3% agarose gels or 5% acrylamide gels and stained with
ethidium bromide.
p53 mutation detection
DNA was amplified in separate PCR reactions for all p53
coding exons (2–11) and flanking regulatory regions.
Primer sequences and PCR conditions are available from
the authors on request. PCR products were purified and
sequenced using Big Dye Terminator chemistry (Perkin-
Elmer, Boston, MA), and run on an ABI 3100 DNA
sequencer (Applied Biosytstems, Foster City, CA).
Sequencing data were analyzed using Sequencher soft-
ware (Gene Codes Corporation, Ann Arbor MI). Muta-
tions were confirmed with a separate sequencing reaction
and were compared to the UMP TP53 mutation database
at http://p53.free.fr/.
Statistics and Survival
Two by two comparisons were evaluated with the Fisher's
exact tests and larger contingency tables were evaluated
with Chi Square. Two-tailed p values were generated with
InStat (Graphpad Software, San Diego, CA). All womenMolecular Cancer 2009, 8:48 http://www.molecular-cancer.com/content/8/1/48
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received primary therapy containing a taxane and plati-
num agent. Overall survival was calculated from the date
of diagnosis until death or last follow-up. Survival curves
were generated according to the Kaplan-Meier method
using Prism (Graphpad Software). Cox regression analysis
was performed using JMP8 (SAS, Cary, NC). Differences
between survival curves were tested with the Log-rank
method. Multi-variate analysis was performed using Cox
proportional hazards modelling using JMP8.
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